Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026

In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat showed a sustained 17.8 mmHg reduction in automated office systolic blood pressure at Week 48 from the Launch-HTN baseline. The excerpt provides no comparator, safety findings, or other trial results.